Benjamin J Oldfield1,2,3, Nicolas Muñoz2, Mark P McGovern4, Melissa Funaro5, Merceditas Villanueva2,6, Jeanette M Tetrault2, E Jennifer Edelman2,6. 1. National Clinician Scholars Program. 2. Department of Medicine. 3. Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut. 4. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California. 5. Harvey Cushing/John Hay Whitney Medical Library, Yale University. 6. Center for Interdisciplinary Research on AIDS, Yale School of Public Health, New Haven, Connecticut, USA.
Abstract
OBJECTIVE: We sought to identify optimal strategies for integrating HIV- and opioid use disorder-(OUD) screening and treatment in diverse settings. DESIGN: Systematic review. METHODS: We searched Ovid MEDLINE, PubMed, Embase, PsycINFO and preidentified websites. Studies were included if they were published in English on or after 2002 through May 2017, and evaluated interventions that integrated, at an organizational level, screening and/or treatment for HIV and OUD in any care setting in any country. RESULTS: Twenty-nine articles met criteria for inclusion, including 23 unique studies: six took place in HIV care settings, 12 in opioid treatment settings, and five elsewhere. Eight involved screening strategies, 22 involved treatment strategies, and seven involved strategies that encompassed screening and treatment. Randomized controlled studies demonstrated low-to-moderate risk of bias and observational studies demonstrated fair to good quality. Studies in HIV care settings (n = 6) identified HIV-related and OUD-related clinical benefits with the use of buprenorphine/naloxone for OUD. No studies in HIV care settings focused on screening for OUD. Studies in opioid treatment settings (n = 12) identified improving HIV screening uptake and clinical benefits with antiretroviral therapy when provided on-site. Counseling intensity for OUD medication adherence or HIV-related risk reduction was not associated with clinical benefits. CONCLUSION: Screening for HIV can be effectively delivered in opioid treatment settings, yet there is a need to identify optimal OUD screening strategies in HIV care settings. Strategies integrating the provision of medications for HIV and for OUD should be expanded and should not be contingent on resources available for behavioral interventions. REGISTRATION: A protocol for record eligibility was developed a priori and was registered in the PROSPERO database of systematic reviews (registration number CRD42017069314).
OBJECTIVE: We sought to identify optimal strategies for integrating HIV- and opioid use disorder-(OUD) screening and treatment in diverse settings. DESIGN: Systematic review. METHODS: We searched Ovid MEDLINE, PubMed, Embase, PsycINFO and preidentified websites. Studies were included if they were published in English on or after 2002 through May 2017, and evaluated interventions that integrated, at an organizational level, screening and/or treatment for HIV and OUD in any care setting in any country. RESULTS: Twenty-nine articles met criteria for inclusion, including 23 unique studies: six took place in HIV care settings, 12 in opioid treatment settings, and five elsewhere. Eight involved screening strategies, 22 involved treatment strategies, and seven involved strategies that encompassed screening and treatment. Randomized controlled studies demonstrated low-to-moderate risk of bias and observational studies demonstrated fair to good quality. Studies in HIV care settings (n = 6) identified HIV-related and OUD-related clinical benefits with the use of buprenorphine/naloxone for OUD. No studies in HIV care settings focused on screening for OUD. Studies in opioid treatment settings (n = 12) identified improving HIV screening uptake and clinical benefits with antiretroviral therapy when provided on-site. Counseling intensity for OUD medication adherence or HIV-related risk reduction was not associated with clinical benefits. CONCLUSION: Screening for HIV can be effectively delivered in opioid treatment settings, yet there is a need to identify optimal OUD screening strategies in HIV care settings. Strategies integrating the provision of medications for HIV and for OUD should be expanded and should not be contingent on resources available for behavioral interventions. REGISTRATION: A protocol for record eligibility was developed a priori and was registered in the PROSPERO database of systematic reviews (registration number CRD42017069314).
Authors: Benjamin J Oldfield; Nicolas Muñoz; Nicholas Boshnack; Robert Leavitt; Mark P McGovern; Merceditas Villanueva; Jeanette M Tetrault; E Jennifer Edelman Journal: J Subst Abuse Treat Date: 2018-11-20
Authors: William E Cunningham; Nancy L Sohler; Carol Tobias; Mari-lynn Drainoni; Judith Bradford; Cynthia Davis; Howard J Cabral; Chinazo O Cunningham; Lois Eldred; Mitchell D Wong Journal: Med Care Date: 2006-11 Impact factor: 2.983
Authors: David A Fiellin; Linda Weiss; Michael Botsko; James E Egan; Frederick L Altice; Lauri B Bazerman; Amina Chaudhry; Chinazo O Cunningham; Marc N Gourevitch; Paula J Lum; Lynn E Sullivan; Richard S Schottenfeld; Patrick G O'Connor Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Michael S Saag; Constance A Benson; Rajesh T Gandhi; Jennifer F Hoy; Raphael J Landovitz; Michael J Mugavero; Paul E Sax; Davey M Smith; Melanie A Thompson; Susan P Buchbinder; Carlos Del Rio; Joseph J Eron; Gerd Fätkenheuer; Huldrych F Günthard; Jean-Michel Molina; Donna M Jacobsen; Paul A Volberding Journal: JAMA Date: 2018-07-24 Impact factor: 56.272
Authors: Hannah K Knudsen; Jennifer Cook; Michelle R Lofwall; Sharon L Walsh; Jamie L Studts; Jennifer R Havens Journal: Subst Abuse Treat Prev Policy Date: 2017-08-16
Authors: Fiona Leh Hoon Chuah; Victoria Elizabeth Haldane; Francisco Cervero-Liceras; Suan Ee Ong; Louise A Sigfrid; Georgina Murphy; Nicola Watt; Dina Balabanova; Sue Hogarth; Will Maimaris; Laura Otero; Kent Buse; Martin McKee; Peter Piot; Pablo Perel; Helena Legido-Quigley Journal: Health Policy Plan Date: 2017-11-01 Impact factor: 3.344
Authors: Richard A Teran; Adam W Carrico; Keith J Horvath; Martin J Downing; Mary Ann Chiasson; Suzan M Walters; Sabina Hirshfield Journal: Arch Sex Behav Date: 2019-10-19
Authors: Jessica J Wyse; Kathleen A McGinnis; E Jennifer Edelman; Adam J Gordon; Ajay Manhapra; David A Fiellin; Brent A Moore; P Todd Korthuis; Amy J Kennedy; Benjamin J Oldfield; Julie R Gaither; Kirsha S Gordon; Melissa Skanderson; Declan T Barry; Kendall Bryant; Stephen Crystal; Amy C Justice; Kevin L Kraemer Journal: AIDS Behav Date: 2021-09-08
Authors: Thibaut Davy-Mendez; Varada Sarovar; Tory Levine-Hall; Alexandra N Lea; Stacy A Sterling; Felicia W Chi; Vanessa A Palzes; Kendall J Bryant; Constance M Weisner; Michael J Silverberg; Derek D Satre Journal: Drug Alcohol Depend Date: 2021-09-28 Impact factor: 4.492
Authors: Kathleen A McGinnis; David A Fiellin; Melissa Skanderson; Yih-Ing Hser; Gregory M Lucas; Amy C Justice; Janet P Tate Journal: Drug Alcohol Depend Date: 2019-09-04 Impact factor: 4.492
Authors: Shannon N Ogden; Miriam Th Harris; Ellen Childs; Pablo K Valente; Alberto Edeza; Alexandra B Collins; Mari-Lynn Drainoni; Matthew J Mimiaga; Katie B Biello; Angela R Bazzi Journal: Int J Drug Policy Date: 2021-05-10
Authors: Amy J Kennedy; Kathleen A McGinnis; Jessica S Merlin; E Jennifer Edelman; Adam J Gordon; P Todd Korthuis; Melissa Skanderson; Emily C Williams; Jessica Wyse; Benjamin Oldfield; Kendall Bryant; Amy Justice; David A Fiellin; Kevin L Kraemer Journal: J Subst Abuse Treat Date: 2021-05-29
Authors: E Jennifer Edelman; James Dziura; Yanhong Deng; Krysten W Bold; Sean M Murphy; Elizabeth Porter; Keith M Sigel; Jessica E Yager; David M Ledgerwood; Steven L Bernstein Journal: Contemp Clin Trials Date: 2021-03-29 Impact factor: 2.226
Authors: Jongyeon Kim; Catherine R Lesko; Anthony T Fojo; Jeanne C Keruly; Richard D Moore; Geetanjali Chander; Bryan Lau Journal: Clin Infect Dis Date: 2021-12-06 Impact factor: 20.999